Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070570 | 0.85 | ADORA3 (0.54) | NPC1RAB9AMEN1KMT2AADORA3 | |
| SCHEMBL4063747 | 0.84 | GAA (0.41) | L3MBTL1GAANPC1RAB9AMEN1 | |
| SCHEMBL4070413 | 0.80 | ALDH1A1 (0.43) | L3MBTL1GAARAB9AKMT2AHPGD | |
| SCHEMBL4069309 | 0.77 | RECQL (0.45) | L3MBTL1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL4243904 | 0.75 | KDM4E (0.52) | L3MBTL1GAANPC1RAB9AMEN1 | |
| SCHEMBL4064215 | 0.74 | RAB9A (0.38) | L3MBTL1GAANPC1RAB9AMEN1 | |
| SCHEMBL4073973 | 0.74 | ADORA1 (0.49) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL4065342 | 0.73 | L3MBTL1 (0.45) | L3MBTL1GAAMEN1KMT2AHPGD | |
| SCHEMBL4068090 | 0.72 | EGFR (0.41) | MEN1KMT2A | |
| SCHEMBL4066514 | 0.72 | GAA (0.43) | L3MBTL1GAAMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | claimed |
| EP-1706412-A4 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS CO LTD (KR) | 2009-03-18 | — | — | EP | claimed |
| WO-2008123756-A1 | A PHARMACEUTICAL COMPOSITIONS CONTAINING LACTON TYPE PYRIDINE DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF ISCHEMIA | SK CHEMICALS CO., LTD. (KR) | 2008-10-16 | — | — | WO | claimed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | claimed |
| JP-2007517024-A | — | — | 2007-06-28 | — | — | JP | claimed |
| EP-1706412-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK Chemicals, Co., Ltd. (KR) | 2006-10-04 | — | — | EP | claimed |
| WO-2005063768-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS, CO., LTD. (KR) | 2005-07-14 | — | — | WO | claimed |
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | disclosed |
| EP-1706412-A4 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS CO LTD (KR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008123756-A1 | A PHARMACEUTICAL COMPOSITIONS CONTAINING LACTON TYPE PYRIDINE DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF ISCHEMIA | SK CHEMICALS CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1706412-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK Chemicals, Co., Ltd. (KR) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063768-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS, CO., LTD. (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | IL5, IL1B, P2RY4 | L3MBTL1 4883/4885GAA 3796/4885NPC1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.